NO20053623L - Derivater av prostaglandiner for behandling av abdominalt ubehag - Google Patents

Derivater av prostaglandiner for behandling av abdominalt ubehag

Info

Publication number
NO20053623L
NO20053623L NO20053623A NO20053623A NO20053623L NO 20053623 L NO20053623 L NO 20053623L NO 20053623 A NO20053623 A NO 20053623A NO 20053623 A NO20053623 A NO 20053623A NO 20053623 L NO20053623 L NO 20053623L
Authority
NO
Norway
Prior art keywords
treatment
prostaglandins
derivatives
abdominal discomfort
chloride channel
Prior art date
Application number
NO20053623A
Other languages
English (en)
Other versions
NO20053623D0 (no
NO335441B1 (no
Inventor
Ryuji Ueno
Sachiko Kuno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053623(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NO20053623D0 publication Critical patent/NO20053623D0/no
Publication of NO20053623L publication Critical patent/NO20053623L/no
Publication of NO335441B1 publication Critical patent/NO335441B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet en ny anvendelse av en kloridkanalåpner, spesielt en prostaglandinforbindelse, for behandling av abdominalt ubehag. Videre er det beskrevet en ny anvendelse av en kloridkanalåpner, spesielt en prostaglandinforbindelse, for behandling av funksjonelle gastro-intestinale forstyrrelser.
NO20053623A 2002-12-27 2005-07-26 Anvendelse av en prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av irritabel tarm-syndrom og/eller funksjonell dyspepsi NO335441B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43646202P 2002-12-27 2002-12-27
US43646302P 2002-12-27 2002-12-27
PCT/JP2003/016857 WO2004060377A1 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Publications (3)

Publication Number Publication Date
NO20053623D0 NO20053623D0 (no) 2005-07-26
NO20053623L true NO20053623L (no) 2005-09-26
NO335441B1 NO335441B1 (no) 2014-12-15

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053623A NO335441B1 (no) 2002-12-27 2005-07-26 Anvendelse av en prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av irritabel tarm-syndrom og/eller funksjonell dyspepsi

Country Status (15)

Country Link
US (3) US7795312B2 (no)
EP (2) EP1575596B1 (no)
JP (2) JP4889219B2 (no)
KR (2) KR101164838B1 (no)
CN (1) CN1753680B (no)
AR (1) AR042670A1 (no)
AU (1) AU2003292556B2 (no)
BR (1) BRPI0317740B8 (no)
CA (1) CA2510051C (no)
ES (1) ES2591252T3 (no)
MX (1) MXPA05006981A (no)
NO (1) NO335441B1 (no)
NZ (1) NZ541110A (no)
TW (1) TWI336254B (no)
WO (1) WO2004060377A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
RU2468800C2 (ru) * 2005-04-12 2012-12-10 Сукампо Аг Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
WO2008029949A1 (en) 2006-09-06 2008-03-13 Sucampo Ag Method and composition for promoting gastrointestinal bicarbonate secretion
JP2010519177A (ja) * 2007-02-27 2010-06-03 スキャンポ・アーゲー ミトコンドリアを保護するための組成物および方法
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA2870252A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
AU2013331380B2 (en) 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2041417C (en) * 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DE69714698T2 (de) 1996-06-10 2002-12-05 Sucampo Ag Endothelin-antagonisten
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
AU739343B2 (en) * 1997-11-28 2001-10-11 Sucampo Ag Endothelin antagonist
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
EP1220849B1 (en) * 1999-10-15 2004-05-19 Sucampo AG Bicyclic compounds composition and method for stabilizing the same
AU4472701A (en) * 2000-04-06 2001-10-23 Sucampo Ag Bile secretion promoting composition
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
TWI324589B (en) * 2001-05-18 2010-05-11 Sucampo Ag Halogenated bioactive lipid compound
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener

Also Published As

Publication number Publication date
BRPI0317740B1 (pt) 2018-09-18
BRPI0317740B8 (pt) 2021-05-25
NO20053623D0 (no) 2005-07-26
BR0317740A (pt) 2005-11-22
US20100298424A1 (en) 2010-11-25
NZ541110A (en) 2008-11-28
TWI336254B (en) 2011-01-21
KR101164838B1 (ko) 2012-07-11
JP2012031202A (ja) 2012-02-16
KR20120045051A (ko) 2012-05-08
KR20050086950A (ko) 2005-08-30
MXPA05006981A (es) 2005-12-14
EP1575596B1 (en) 2016-06-22
EP1575596A1 (en) 2005-09-21
EP2281564A3 (en) 2012-09-05
CA2510051C (en) 2016-07-05
ES2591252T3 (es) 2016-11-25
CN1753680B (zh) 2010-12-08
JP2006513232A (ja) 2006-04-20
AU2003292556B2 (en) 2009-09-10
CN1753680A (zh) 2006-03-29
US20130217770A1 (en) 2013-08-22
US7795312B2 (en) 2010-09-14
CA2510051A1 (en) 2004-07-22
JP4889219B2 (ja) 2012-03-07
TW200418491A (en) 2004-10-01
US20040138308A1 (en) 2004-07-15
AR042670A1 (es) 2005-06-29
WO2004060377A1 (en) 2004-07-22
NO335441B1 (no) 2014-12-15
AU2003292556A1 (en) 2004-07-29
EP2281564A2 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
NO20053623L (no) Derivater av prostaglandiner for behandling av abdominalt ubehag
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
RS52625B (en) FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
UA88773C2 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
WO2003070163A3 (en) Prostacyclin derivatives for treating cancer
DK1485360T3 (da) Natriumkanalblokkere
ATE440603T1 (de) 8-hydroxychinolinderivate
AU2003229953A1 (en) Phthalazinone derivatives
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
HK1072357A1 (en) Stoma measuring device
NO20062663L (no) Nukleinsyre som spesifikt binder bioaktivt ghrelin
UA90496C2 (ru) 18-метил-19-нор-17-прегн-4-эн-21,17-карболактоны, а также лекарственный препарат, который их содержит
HK1087040A1 (en) Compounds for the treatment of metabolic disorders
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
ATE399770T1 (de) Tachykininrezeptorantagonisten
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
DE602005011267D1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
SG139747A1 (en) Inhibitors of the mutant form of kit
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
IT1318667B1 (it) Medicamento antinfiammatorio.
BRPI0412694A (pt) compostos
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
ATE539756T1 (de) Prostaglandinsubstanzen für die behandlung von fettsucht
SE0200198D0 (sv) New use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees